Akums Drugs and Pharmaceuticals Ltd. shares were in focus on Monday after the pharmaceutical company announced strong financial results for the first quarter of fiscal year 2026-27. The stock rose more than 5% in morning trading, adding to its remarkable gains over the past six months.
Akums Drugs’ shares are trading at around Rs 732 each on the NSE and were at Rs 697.45 at close. A strong growth in consolidated net profit and operating profitability, double-digit revenue growth, and a significant performance improvement were among the reasons for the high share price growth among Akums Drugs shares.
The stock has already posted a 57% return in the last six months, and the recent quarterly numbers are of great interest for investors to get an idea of the extent to which the company’s earnings momentum can sustain the shares’ stock price rally.
Akums Drugs Q1 profit rises 57.5% on a large margin
Akums Drugs reported a 57.5% year-on-year increase in consolidated net profit to Rs 100 crore for the June quarter, compared with Rs 63.5 crore in the same quarter of the previous year.
Profit growth was much faster than the company’s revenue growth; this indicates that operating performance and profitability improved significantly in the quarter of the year.
The consolidated revenue from operations increased by 13.9% year-on-year to Rs 1,167 crore, against Rs 1,024 crore in the year-ago period.
The combination of healthy revenue expansion and stronger operating margins helped the company deliver a substantially higher bottom line.
EBITDA Jumps 35.5%
Akums Drugs also showed strong growth at the operating level.
Consolidated EBITDA increased 35.5% year-on-year to Rs 175 crore compared to Rs 129 crore in the same quarter last year.
The EBITDA margin for the company is now 15% (up from 12.6% a year ago).
That is a 240 basis points improvement and shows the company’s improving operating profitability during the quarter.
The margin expansion is very important since it allowed the company to grow profit much faster than revenue. If they can sustain this operating profitability improvement, that could be a key factor for earnings growth in the next few quarters.
The stock has gained 57% in six months
The good quarterly numbers come after a strong rally in Akums Drugs shares.
The stock is up 57% in the past six months. The rally has picked up a lot more in recent months (the stock has risen more than 64% so far in 2026).
In a shorter time frame, Akums Drugs shares have risen over 7.7% since the end of last week.
Thus, Monday’s intraday rally expands an already great upward movement and indicates that investors are liking what’s going on with the company’s recent earnings.
But the sharp rise also means that expectations of future earnings growth may be elevated. Investors will thus be watching whether the company can maintain recent improvement in margins and profitability.
Valuation is still a factor
Following the recent rally, Akums Drugs is trading at a price-to-earnings multiple of close to 37.51 times.
The company’s market capitalisation was around Rs 11,535.4 crore at the end of the last trading session.
The valuation suggests that the market is assigning a premium to the company’s earnings prospects. If revenue continues to grow and margins continue to grow as well, investors might have a reason to reconsider the premium on the stock.
The fundamental improvement of the company will need to continue at a rate that supports the company’s current valuation, as the stock is up so much.
What are the factors that drove Q1 performance?
The June-quarter results show the results of growth and profitability improvement in a positive way.
Revenue increased 13.9% with a good base for earnings growth. Even more importantly, EBITDA grew 35.5% faster than revenue and EBITDA margin rose from 12.6% to 15%.
The operating leverage was also reflected in the bottom line, with net profit up 57.5%.
The numbers show that Akums Drugs was able to make profits while growing its top line. Investors will know if growth is sustainable or not if margin growth is not.
What Investors Should Watch Next
After a 57% six-month rally, the stock enters the next phase with a stronger earnings profile but also higher market expectations.
Investors will be monitoring revenue growth, EBITDA margins, profit growth, and management commentary in the future to verify that the June-quarter improvement is sustainable.
The company will need to be able to maintain margins around the recently improved level, and that is the most critical for them. A continuation of double-digit revenue growth and healthy operating leverage could add to earnings.
But any sharp downturn in revenue growth or margin contraction would have some effect on the stock, as it has been on the rise since the beginning and is still at a relatively high valuation.
For now, Akums Drugs has had a strong start to FY27. Net profit growth of 57.5%, revenue growth of 13.9%, and a 240-basis-point improvement in EBITDA margin are good news from a fundamental perspective.
The stock’s more than 57% rise in six months and more than 64% increase in 2026 will make investors want to know if future earnings can keep up with the strong share-price performance.
Comments
Please to leave a comment on this article.